| PTO Form 1581 (Rev 9/2005) |
| OMB No. 0651-0054 (Exp. 09/30/2011) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
| SERIAL NUMBER |
77116028 |
| LAW OFFICE ASSIGNED |
LAW OFFICE 117 |
| MARK SECTION |
| STANDARD CHARACTERS |
YES |
| USPTO-GENERATED IMAGE |
YES |
| LITERAL ELEMENT |
CHRONSEAL |
| OWNER SECTION (1st owner)(no change) |
| OWNER SECTION (2nd owner)(no change) |
| GOODS AND/OR SERVICES SECTION |
| INTERNATIONAL CLASS |
005 |
| CURRENT IDENTIFICATION |
Topical wound healing medicament containing a recombinant skin growth factor protein for treatment purposes |
| GOODS OR SERVICES |
KEEP ALL LISTED |
| EXTENSION SECTION |
| EXTENSION NUMBER |
4 |
| ONGOING EFFORT |
product or service research or development |
| ALLOWANCE MAIL DATE |
03/25/2008 |
| STATEMENT OF USE |
NO |
| PAYMENT SECTION |
| NUMBER OF CLASSES |
1 |
| SUBTOTAL AMOUNT |
150 |
| TOTAL AMOUNT |
150 |
| SIGNATURE SECTION |
ORIGINAL
PDF FILE |
http://tgate:8080/PDF/ESU/2010/03/04/20100304133425772032-77116028-001_001/hw_63139240150-125114821_._KRNGL.001TUS_4th_Ext_req.pdf |
CONVERTED
PDF FILE(S)
(1 page) |
\\TICRS\EXPORT9\IMAGEOUT9\771\160\77116028\xml1\ESU0002.JPG |
| SIGNATORY'S NAME |
Anders Vahlne |
| SIGNATORY'S POSITION |
CEO |
| SIGNATORY'S NAME |
Kunio Iwatani |
| SIGNATORY'S POSITION |
President & CEO |
| FILING INFORMATION |
| SUBMIT DATE |
Thu Mar 04 13:34:25 EST 2010 |
| TEAS STAMP |
USPTO/ESU-XX.XXX.XXX.XXX-
20100304133425772032-7711
6028-4601b9e5c6fafeebfb5b
81632c6b6e9e5-CC-13105-20
100304125114821794 |
| PTO Form 1581 (Rev 9/2005) |
| OMB No. 0651-0054 (Exp. 09/30/2011) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: CHRONSEAL
SERIAL NUMBER: 77116028
The applicants, KRINGLE PHARMA, INC., having an address of
18F, SENRI ASAHI HANKYU BLDG.
TOYONAKA, OSAKA, 5600082
Japan
and KRINGLE PHARMA EUROPE AB, having an address of
HALSOVAGEN 7
HUDDINGE, SE141 57
Sweden
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 03/25/2008.
For International Class 005:
Current identification: Topical wound healing medicament containing a recombinant skin growth factor protein for treatment purposes
The applicant has a continued bona fide intention to use or use through the applicant's related company or licensee the mark in commerce on or in connection with all of the goods and/or services
listed in the Notice of Allowance or as subsequently modified for this specific class.
This is the fourth extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods and/or services covered by
the extension request: product or service research or development
A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.
Declaration
Original PDF file:
http://tgate:8080/PDF/ESU/2010/03/04/20100304133425772032-77116028-001_001/hw_63139240150-125114821_._KRNGL.001TUS_4th_Ext_req.pdf
Converted PDF file(s) (1 page)
Signature File1
Signatory's Name: Anders Vahlne
Signatory's Position: CEO
Signatory's Name: Kunio Iwatani
Signatory's Position: President & CEO
RAM Sale Number: 13105
RAM Accounting Date: 03/04/2010
Serial Number: 77116028
Internet Transmission Date: Thu Mar 04 13:34:25 EST 2010
TEAS Stamp: USPTO/ESU-XX.XXX.XXX.XXX-201003041334257
72032-77116028-4601b9e5c6fafeebfb5b81632
c6b6e9e5-CC-13105-20100304125114821794
